Professor William Klein - Phase 1 clinical trial begins for ACU193 for individuals with early Alzheimer’s disease
October 7, 2021
Neurobiology Professor William Klein, co-founder of Acumen, announced on October, 7, 2021 - First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease.